GlassScriptPhysician profile
Sheila L Tecson
NPI 1497876437
$3,680.05
in general payments reported to CMS, 2019-2025
32 companies · $226 in 2025
The $226 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $633 · 2020: $381 · 2022: $286 · 2023: $1,151 · 2024: $1,002 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,379.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $745.32 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $649.36 | 2019-2025 | Prolia, Repatha, Evenity |
| Lilly USA, LLC | $262.46 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $260.28 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $233.69 | 2024 | Qelbree |
| Glaxosmithkline, LLC. | $159.77 | 2019-2025 | Shingrix, Arexvy |
| Currax Pharmaceuticals LLC | $138.26 | 2019-2025 | Contrave, Onzetra Xsail, Nexlizet |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.34 | 2020-2024 | Cycloset, Xifaxan |
| Esperion Therapeutics, INC. | $121.11 | 2022-2023 | Nexletol |
| Allergan, INC. | $101.79 | 2019-2020 | |
| Intuitive Surgical, INC. | $92.21 | 2023 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $70.64 | 2020-2024 | Farxiga |
| Exact Sciences Corporation | $63.88 | 2024-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $62.26 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $61.97 | 2019-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $57.97 | 2019-2020 | |
| Dexcom, INC. | $43.24 | 2023 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.58 | 2019 | |
| Abbvie INC. | $37.82 | 2022-2023 | Qulipta |
| Merck Sharp & Dohme LLC | $37.53 | 2019-2020 | |
| Medacta USA, INC. | $35.88 | 2020 | |
| Eisai INC. | $34.38 | 2019 | |
| Biosense Webster, INC. | $34.27 | 2023 | Carto 3 |
| Ibsa Pharma INC. | $32.88 | 2022-2023 | Tirosint, Licart |
| Abbott Laboratories | $32.77 | 2024 | Freestyle Libre 3 |
| Phadia US INC. | $32.21 | 2019-2024 | Immunocap |
| Sunovion Pharmaceuticals INC. | $29.91 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.36 | 2019 | |
| Endo Pharmaceuticals INC. | $19.68 | 2019 | |
| Daiichi Sankyo INC. | $16.94 | 2019 | |
| Amneal Pharmaceuticals LLC | $13.23 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheila Tecson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.